Emergent gets $23 million additional order for vaccine production

Emergent gets $23 million additional order for vaccine production

By Administrator_ India

Capital Sands

Emergent BioSolutions Inc said late on Sunday that a key U.S. agency has increased an order, related to the manufacturing of the Johnson & Johnson COVID-19 vaccine, by $23 million.

The amount will be used to purchase biologics equipment specific to J&J’s vaccine and support the potential manufacturing expansion at the company’s Baltimore Bayview facility, the company said in a statement.

Emergent also said that it will agree to a mutual ramp down of manufacturing of AstraZeneca ( Plc’s COVID-19 vaccine bulk drug substance.

Related Posts
On strong US demand and China optimism, oil is hovering near a 13-week high
Brent oil futures

On Thursday, oil prices remained at 13-week highs, supported by strong demand in the world's largest consumer, the United States, Read more

Dollar, Euro Down as U.S. Refutes Russian Ukraine Claims
Dollar Euro Down as U.S. Refutes Russian Ukraine Claims

The dollar was down on Thursday morning in Asia, alongside the euro. Investors are digesting the U.S. doubts that Russia Read more

Asia stocks, oil struggle as Omicron worries weigh
Asia stocks, oil struggle as Omicron worries weigh

Asian stock markets were generally weaker  in holiday-thinned trading on Monday, as uncertainty over the economic impact of the Omicron Read more

US tells citizens to leave India as Covid-19 overwhelms hospitals
Vaccine inequity deepens in young: 85% of those jabbed are in just seven states

By Administrator_India Capital Sands The U.S. government told its citizens to leave India as soon as possible because of the Read more

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x